New drug combination slows tumor growth for recurrent ovarian cancer
Monday, June 6, 2011 - 11:00
in Health & Medicine
Bevacizumab (Avastin) in combination with chemotherapy resulted in a clinical benefit for patients with recurrent ovarian cancer, according to a new study. Results from the phase III "OCEANS" trial were presented today by the lead author, Carol Aghajanian, MD, of Memorial Sloan-Kettering Cancer Center, at the 2011 annual meeting of the American Society of Clinical Oncology.